BR112022018596A2 - Formas cristalinas de um agonista de receptor farnesoide x - Google Patents

Formas cristalinas de um agonista de receptor farnesoide x

Info

Publication number
BR112022018596A2
BR112022018596A2 BR112022018596A BR112022018596A BR112022018596A2 BR 112022018596 A2 BR112022018596 A2 BR 112022018596A2 BR 112022018596 A BR112022018596 A BR 112022018596A BR 112022018596 A BR112022018596 A BR 112022018596A BR 112022018596 A2 BR112022018596 A2 BR 112022018596A2
Authority
BR
Brazil
Prior art keywords
farnesoid
receptor agonist
crystalline forms
hydroxyazetidine
octan
Prior art date
Application number
BR112022018596A
Other languages
English (en)
Inventor
D Smith Nicholas
Mansfield Robert
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of BR112022018596A2 publication Critical patent/BR112022018596A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMAS CRISTALINAS DE UM AGONISTA DO RECEPTOR FARNESOIDE X. É aqui descrito o agonista do receptor farnesoide X, 4-((4-(1-(terc-butil)-1H-pirazol-4-il)piridin-2-il)((4-(4-metoxi-3-metilfenil)biciclo[2.2.2]octan-1-il)metil)carbamoil)ciclohexil 3-hidroxiazetidina-trans-1-carboxilato, incluindo formas cristalinas e sais, solvatos e formulações farmaceuticamente aceitáveis dos mesmos.
BR112022018596A 2020-03-18 2021-03-17 Formas cristalinas de um agonista de receptor farnesoide x BR112022018596A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991213P 2020-03-18 2020-03-18
PCT/US2021/022790 WO2021188692A1 (en) 2020-03-18 2021-03-17 Crystalline forms of a farnesoid x receptor agonist

Publications (1)

Publication Number Publication Date
BR112022018596A2 true BR112022018596A2 (pt) 2023-03-07

Family

ID=77771306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018596A BR112022018596A2 (pt) 2020-03-18 2021-03-17 Formas cristalinas de um agonista de receptor farnesoide x

Country Status (13)

Country Link
US (1) US20230147756A1 (pt)
EP (1) EP4121010A4 (pt)
JP (1) JP2023518399A (pt)
KR (1) KR20220155356A (pt)
CN (1) CN115666521A (pt)
AR (1) AR121596A1 (pt)
AU (1) AU2021236648A1 (pt)
BR (1) BR112022018596A2 (pt)
CA (1) CA3171987A1 (pt)
IL (1) IL296532A (pt)
MX (1) MX2022011582A (pt)
TW (1) TW202144332A (pt)
WO (1) WO2021188692A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056271A (zh) 2018-09-18 2021-06-29 梅塔科林公司 法尼醇x受体激动剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US10961198B2 (en) * 2017-03-15 2021-03-30 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
CA3056019A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN113056271A (zh) * 2018-09-18 2021-06-29 梅塔科林公司 法尼醇x受体激动剂及其用途
WO2020061117A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
EP4121010A4 (en) 2024-04-10
CN115666521A (zh) 2023-01-31
IL296532A (en) 2022-11-01
TW202144332A (zh) 2021-12-01
US20230147756A1 (en) 2023-05-11
JP2023518399A (ja) 2023-05-01
MX2022011582A (es) 2022-12-13
AR121596A1 (es) 2022-06-22
EP4121010A1 (en) 2023-01-25
KR20220155356A (ko) 2022-11-22
WO2021188692A1 (en) 2021-09-23
AU2021236648A1 (en) 2022-10-13
CA3171987A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
BR112022018596A2 (pt) Formas cristalinas de um agonista de receptor farnesoide x
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
NI201900053A (es) Formas cristalinas de un inhibidor de magl
AR030190A1 (es) Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
UY39800A (es) N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio
MX2021003083A (es) Formas cristalinas de un agonista del receptor de farnesoide x.
CO2022005861A2 (es) Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
ECSP109883A (es) Combinaciones sinérgicas de antagonistas de vr-1 e inhibidores de cox-2
NO20060510L (no) Emulgerende systemer inneholdende azetidinderivater
PE20211818A1 (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal
AR122175A1 (es) Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
HUP0105201A2 (hu) Férfiklimax kezelése ösztrogén agonistákat/antagonistákat és tesztoszteront tartalmazó gyógyászati készítmények alkalmazásával
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
UY28893A1 (es) Una composicion farmaceutica antimicobacteriana
BR112022018553A2 (pt) Formulações de um agonista do receptor x farnesoide
ES2113533T3 (es) Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal.
ZA202302271B (en) Dual regulator for mglur5 and 5-ht2a receptors and use thereof
ZA202204943B (en) Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
MX2021008321A (es) Composiciones farmaceuticas que comprenden (s)-4-(4-(4-(((2-(2,6-d ioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperaz in-1-il)-3-fluorobenzonitrilo y metodos para su uso.
MX2022012934A (es) Agente terapeutico para cancer de mama.
MX2023012911A (es) Metodos de tratamiento del mieloma multiple usando terapia combinada.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]